BofA analyst Jason Zemansky raised the firm’s price target on BridgeBio (BBIO) to $54 from $50 and keeps a Buy rating on the shares. After speaking to key opinion leaders, the firm has greater conviction in encaleret’s opportunity and more clarity into ‘418’s potential for upside, leading it to raise forecasts, the analyst tells investors.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO:
- BridgeBio Pharma’s Promising Growth Potential Driven by Attruby and Upcoming Pivotal Readouts for Encaleret and BBP-418
- TipRanks’ ‘Perfect 10’ Picks: 2 Top-Scoring Stocks That Are Ticking Every Box
- BridgeBio Pharma Annual Meeting Approves Key Proposals
- Avidity, BridgeBio, Coty, SAGE, Alkermes: Trending by Analysts
- BridgeBio initiated with an Outperform at Wolfe Research